Active-ingredient Dossier
Imatinib Mesilate
Active-ingredient Dossier for Imatinib Mesilate (tyrosine kinase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: ARX-IMATINIB
- Brand: IMANIB
- Brand: IMATINIB
- Brand: APO-IMATINIB
- Brand: APOTEX-IMATINIB
- Brand: HEVEC
- Therapeutic area: Oncology
What is
Imatinib Mesilate Imatinib Mesilate is a tyrosine kinase inhibitor.
Australian brands containing
Imatinib Mesilate — IMATAB — IMATINIB — ARX-IMATINIB — GILMAT — IMANIB — IMATINIB GH — Imatinib-DRLA — IMATINIB-TEVA
Therapeutic areas
Imatinib Mesilate is registered in oncology, with 20 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by eight sponsors: Hetero, Dr Reddys Laboratories, Cipla, Arrotex Pharmaceuticals, Sun Pharma, and Juno Pharmaceuticals.
PBS and regulatory activity
Two brands have PBAC outcomes on record, with the latest outcome dated 1 November 2021. No brands have AusPARs on record.